Application of small molecule compounds in the preparation of anti-tumor drugs
Through graphite structured nanomaterial matrix and MALDI-MS technology, combined with computer screening methods, the problems of high background noise and poor signal reproducibility in MALDI-MS technology were solved, and high accuracy and rapid screening of small molecule compounds were achieved. Small molecule compounds with anti-tumor activity and break through the blood-brain barrier, with the advantages of pharmacokinetic detection.
Patent Information
- Application Number
- CN202210514070.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-04-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-04-21
AI Technical Summary
The existing MALDI-MS technology has high background noise, poor signal reproducibility, and is difficult to be used for analysis of natural products and biological samples in small molecule analysis. The computer screening method lacks actual experimental conditions, resulting in low mass spectrometry sensitivity and poor repetition. .
Graphite structure nanomaterials were used as matrix and combined with MALDI-MS detection. By mixing candidate inhibitors with hexokinase 2 and glucose, adding them dropwise to the surface of graphite nanomaterials for mass spectrometry detection, hexokinase 2 inhibitors were screened out The candidate compounds were screened using LigPrep, Glide-SP, GlideXP and ACD/ADME software packages, and finally molecular clustering was performed through Discovery Studio 2.5 to obtain small-molecular compounds with anti-tumor activity.
High accuracy and rapid screening of small-molecular compounds is achieved, and 1,836 samples can be analyzed within 5.1 hours to obtain small-molecular drugs with high brain tumor growth inhibition activity, break through the blood-brain barrier, and have a competitive advantage in pharmacokinetic detection.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3
Abstract
Description
[0001] This application is a divisional application of application number 202110429488.X, application date April 21, 2021, and name “A screening method for hexokinase 2 inhibitors and the use of small molecule compounds in the preparation of anti-tumor drugs”. Technical Field
[0002] The present invention belongs to the technical field of analysis and detection, and in particular relates to the application of small molecule compounds in the preparation of anti-tumor drugs. Background Art
[0003] Matrix-assisted laser desorption ionization mass spectrometry is a soft ionization technique that has achieved great success in the rapid analysis of biomacromolecules (nucleic acids, proteins, peptides, etc.) and polymers. However, the traditional organic matrix commonly used in MALDI-MS (matrix-assisted laser desorption ionization mass spectrometry) will produce high background noise when the mass-to-charge ratio is lower than 700, interfering with the signal of small molecules in mass spectrometry analysis. In addition, the organic matrix tends to form randomly distributed crystals of different sizes (on the order of tens of microns), which reduces the reproducibility of the signal. Therefore, the development of MALDI in the detection and application of small molecule analysis is seriously hindered.
[0004] In the prior art reports, inorganic nanomaterials or inorganic nanostructured surfaces have been used as suitable matrices to replace organic matrices in MALDI, including silicon, alloys, metal oxides, carbon nanomaterials, etc. They can overcome the background interference of traditional organic matrices in the low molecular weight region, but it is difficult to perform sensitive detection and precise imaging of small molecules in the body, and cannot be used for rapid screening of new drugs.
[0005] Although these materials have made great improvements in the analysis of small molecules, the mass spectra obtained are not very sensitive and have poor reproducibility, so they still have major flaws in the analysis of natural products, blood, biological samples and direct tissue imaging.
[0006] Although the process of computer screening to obtain target molecules is fast, the computer-simulated drug environment lacks actual experimental conditions such as reagents, which is still a shortcoming of this method. Commonly used fluorescence or ultraviolet absorption methods require additional artificial substrate modification or coupling enzymes, which will cause problems of interfering with candidate drug signals. The current optimal LC-MS system equipped with ultrafast gradient conventional short columns is still limited in speed, analyzing only 768 blood samples in 3.75 hours (excluding a large amount of pretreatment time). Summary of the invention
[0007] In view of this, the object of the present invention is to provide a use of a small molecule compound in the preparation of an anti-tumor drug, wherein the method is rapid and highly accurate.
[0008] The present invention provides a method for screening a hexokinase 2 inhibitor, comprising the following steps:
[0009] Mixing the candidate inhibitor and a buffer, incubating, and terminating the reaction to obtain a post-reaction solution; the buffer comprises hexokinase 2 and glucose;
[0010] The reaction solution was mixed with an equal volume of glucose-1- 13 C mixed to obtain the analyte;
[0011] The analyte is dropped onto the surface of the graphite structure nanomaterial matrix, and after drying, MALDI-MS detection is performed to screen and obtain a hexokinase 2 inhibitor.
[0012] In the present invention, the screening conditions are:
[0013] The concentration of the candidate inhibitor aqueous solution is 20 μmol / L, and the inhibition rate of hexokinase 2 activity is ≥ 25%;
[0014] Inhibition rate = (1-B / A) × 100%;
[0015] A is the glucose concentration in the solution before the reaction without adding the inhibitor minus the glucose concentration in the solution after the reaction without adding the inhibitor;
[0016] B is the glucose concentration in the solution before the reaction with the inhibitor minus the glucose concentration in the solution after the reaction with the inhibitor;
[0017] Glucose concentration in reaction solution = ([glucose + Na] + Mass spectrometry signal intensity / [glucose-1- 13 C+Na] + mass spectrometry signal intensity) × known glucose-1- 13 C concentration.
[0018] In the present invention, the volume ratio of the candidate inhibitor to the buffer is 1:1;
[0019] The mass ratio of hexokinase 2 to glucose in the buffer is (0.245-0.255) g:0.5 mmol;
[0020] The concentration of the candidate inhibitor is 1 μmol / L to 1000 μmol / L.
[0021] In the present invention, the incubation temperature is 35-40° C., and the incubation time is 55-65 min.
[0022] In the present invention, the MALDI-MS detection adopts the reflection positive and negative ion mode;
[0023] Experimental parameters for MALDI-MS detection:
[0024] 355nm Nd:YAG laser, laser energy of 30%, corresponding to 57μJ per pulse, laser pulse duration: 3ns, laser spot size of 50-100μm;
[0025] Each sample was tested four times; 3000 laser spots were accumulated for each mass spectrum.
[0026] In the present invention, the graphite structure nanomaterial matrix (GDs) mainly contains three functional groups: hydroxyl (-OH), carbonyl (C=O) and epoxy (COC). The percentage of functional groups on the surface of GDs is: C-OH, 26%; C=O, 13%; COC, 1%. The GDs have good dispersibility, and the particle size distribution is relatively uniform, about 5-6nm, and the height is uniform (height is about 6nm), indicating that the GDs are approximately a cubic block; honeycomb graphite structure; standard hexagonal crystal structure; strong ultraviolet absorption at 337nm and 355nm, covering the most widely used laser wavelength of MALDI-MS.
[0027] In the present invention, the candidate inhibitor is obtained by the following method:
[0028] use The LigPrep module was used for screening to obtain preliminary screening compounds;
[0029] Under the simulation environment with the protonation state parameter of pH=7.0±2.0, the scaling factor of the van der Waals radius set to 1.0, and the maximum atomic charge set to 0.25, the binding affinity of the preliminary target compound and HK2 was first scored and ranked using the Glide-SP mode, and then the top 50,000 compounds were scored using the GlideXP docking mode, and then the ACD / ADME software package was used to predict the ADMET properties of the selected compounds. The top 1,000 compounds docked by Glide XP were filtered to remove those that did not meet the following rules: (1) logP / logD (pH=7.0) <5.5; (2) violation of Lipinski's rule 5 <2; (3) violation of Opera's drug similarity rule <3; (4) the functional group had no toxic, reactive or other undesirable parts defined by the REOS rule;
[0030] Finally, the Find Diversity Molecule module in Discovery Studio 2.5 was used to cluster the remaining molecules according to the Tanimoto distance calculated from the FCFP_4 fingerprint to obtain candidate inhibitors.
[0031] The method provided by the present invention can be applied in the fields of mass spectrometry detection, mass spectrometry imaging, proteomics, metabolomics, drug development, drug analysis and application.
[0032] In the present invention, the above screening method uses a graphite structure nanomaterial matrix as a new matrix, and combines MALDI mass spectrometry technology to identify and measure reactants (or products) of chemical reactions involving various small molecules, thereby screening small molecule compounds with specific chemical structures and activities; the present invention uses the above technology to monitor the absorption and uptake, blood drug concentration, organ distribution of specific small molecule compounds in in vivo experiments, and the chemical structure changes that occur in these processes; the present invention uses the above technology combined with the histomorphological characteristics of the three-dimensional space of living organs, and simultaneously visualizes the various small molecules distributed therein. This method screens small molecule compounds and their derivatives that regulate tumor cell metabolic reprogramming and anti-tumor activity.
[0033] The hexokinase 2 inhibitor obtained by the screening method of the present invention is a small molecule compound and can be applied to the preparation of anti-tumor drugs.
[0034] The present invention also provides the use of small molecule compounds in the preparation of anti-tumor drugs;
[0035] The small molecule compound has structures of Formula 1 to Formula 45:
[0036]
[0037] The structural composition of the above compounds is mainly composed of a carbon chain connecting the two ends of the aromatic group, the carbon chain contains amide, methoxy, hydroxyl, and the aromatic group is substituted by halogen, hydroxyl, epoxy, etc.
[0038]
[0039]
[0040]
[0041] Among the above compounds, Formula 6 to Formula 14 are all derivatives of the small molecule inhibitor of Formula 1, mainly with the six-membered ring side chain substitution on the right side of NH, such as methyl, benzene ring and halogen substitution, etc.; Formula 15 to Formula 23 are all derivatives of the small molecule inhibitor of Formula 2, mainly with the naphthalene ring side chain substitution on the right side of formamide, such as methoxy, five-membered ring substitution, etc. Formula 24 to Formula 29 are all derivatives of the small molecule inhibitor of Formula 3, with the benzene ring phenyl substitution on the right side of NH, N displacement on the benzene ring, carbon chain methyl, benzene ring substitution, etc. Formula 30 to Formula 40 are all derivatives of the small molecule inhibitor of Formula 4, with the carbon chain substitution on the right side of NH, methyl substitution on the benzene ring, etc. Formula 41 to Formula 45 are all derivatives of the small molecule inhibitor of Formula 5, with the benzene ring phenyl substitution on the right side of NH, N displacement on the benzene ring, carbon chain methyl, remote benzene ring substitution, etc.
[0042] In the present invention, the small molecule compound has an inhibitory effect on key proteases in abnormal glycolysis caused by metabolic reprogramming in tumor cells, and is used alone as a drug molecule or in combination with other known drugs to kill tumor cells.
[0043] In the present invention, the small molecule compound can inhibit the abnormal metabolic pathway of tumor cells and hinder their ability to repair damaged DNA during chemotherapy;
[0044] The small molecule compound can break through the limitation of the blood-brain barrier and be taken up and enriched in the tumor site which is difficult for conventional drugs to reach.
[0045] In the present invention, in the case of single administration or continuous multiple administration, the mass spectrometry quantitative analysis of drug molecules is performed on a blood sample of less than 10 microliters, so that a single model animal can complete the data collection of pharmacokinetic (blood drug concentration-time curve). The drug refers to a small molecule compound.
[0046] The present invention provides a method for screening hexokinase 2 inhibitors, comprising the following steps: mixing a candidate inhibitor with a buffer, incubating, terminating the reaction, and obtaining a post-reaction solution; the buffer comprises hexokinase 2 and glucose; mixing the post-reaction solution with an equal volume of glucose-1- 13 C and mixed to obtain the analyte; the analyte is added dropwise to the surface of the graphite structure nanomaterial matrix, and after drying, MALDI-MS detection is performed to screen and obtain hexokinase 2 inhibitors. This method uses graphite structure nanomaterials as a matrix, combined with MALDI-MS detection, ultra-fast screening and detection (analyzing 1836 samples within 5.1 hours); a series of small molecule drugs with high inhibitory activity on brain tumor growth are obtained; small molecule drug efficacy analysis is docked without the need to transfer to other detection platforms. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1Schematic diagram of the GLMSD platform for high-throughput screening of candidate inhibitors of hexokinase 2 (HK2);
[0048] Figure 2 The inhibition rates of 38 candidate inhibitors on HK2 at 4 different concentrations;
[0049] Figure 3 (a) is the structural formula of compound 8, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 8 detected by the GLMSD platform;
[0050] Figure 4 (a) is the structural formula of compound 11, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 11 detected by the GLMSD platform;
[0051] Figure 5 (a) is the structural formula of compound 13, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 13 detected by the GLMSD platform;
[0052] Figure 6 (a) is the structural formula of compound 21, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 21 detected by the GLMSD platform;
[0053] Figure 7 (a) is the structural formula of compound 27, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 27 detected by the GLMSD platform;
[0054] Figure 8-1 The pharmacokinetic data of TMZ are as follows;
[0055] Figure 8-2 Pharmacokinetic data of compound 27;
[0056] Fig. 9 MSI images of drugs and metabolites (compound 27: m / z 499, lactic acid: m / z 113) in brain tissue sections;
[0057] Fig.10(b) is the growth curve of U87MG subcutaneous tumor in nude mice after various treatments to eliminate primary tumors, and the error bars represent mean ± sd, (n = 6); (c) is the survival rate of mice with subcutaneous U87MG tumors after receiving various treatments (n = 6 in each group); (d) is a representative bioluminescence image;
[0058] Fig.11 is the antiproliferative activity of compound 27 on brain glioma cells U87;
[0059] Fig.12 (e) is a schematic diagram of the binding structure of the comp-27-HK complex predicted by Glide XP docking simulation; (f) is a two-dimensional schematic diagram of the binding mode of the comp-27-HK complex with hydrogen bonds and strong hydrophobic interactions;
[0060] Fig.13 is the difference in the interaction scores of compound 27 and 3-Br at each residue (Eintcompd27-Eint3-Br);
[0061] Fig.14 This is a test diagram of the anti-proliferative activity of compound 8, compound 11, compound 13 and compound 21 on brain glioma cells U87;
[0062] Fig.15 Normalization of reprogrammed metabolic pathways in glioma U87 cells after Compound 27 treatment;
[0063] Fig.16 Flow cytometry analysis of compd27-induced apoptosis in U87 cells (Annexin V-FITC / PI staining). DETAILED DESCRIPTION
[0064] In order to further illustrate the present invention, the application of the small molecule compound provided by the present invention in the preparation of anti-tumor drugs is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0065] Example 1
[0066] Sources of 38 candidate inhibitors:
[0067] 1. Compound library acquisition (240,000 compounds, Specs compound library obtained by screening the LigPrep module);
[0068] 2. Compound and HK2 docking simulation (precision mode: standard precision (SP) and extra precision (XP)) are all done by Glide production (protonation state parameters are pH = 7.0 ± 2.0, the scaling factor of the van der Waals radius is set to 1.0, and the maximum atomic charge is set to 0.25.)
[0069] Specific docking process: All compounds were docked with the HK2 structure, and the binding affinity was scored and ranked using the Glide-SP mode. Then, the top 50,000 molecules were scored using the GlideXP docking mode. Subsequently, the ACD / ADME software package was applied to predict the ADMET properties of the selected compounds, and the top 1,000 compounds docked by Glide XP were filtered to remove those that did not meet the following rules: (1) logP / logD (pH = 7.0) < 5.5; (2) violation of Lipinski's rule 5 < 2; (3) violation of Opera's drug similarity rule < 3; (4) functional groups had no toxic, reactive or other undesirable parts defined by the REOS rule. Then, the Find Diversity Molecule module in Discovery Studio 2.5 was used to cluster the remaining molecules according to the Tanimoto distance calculated from the FCFP_4 fingerprint. Finally, the 40 hit compounds with the lowest docking scores were purchased from the Specs library;
[0070] The structural formulas of the 40 compounds are as follows:
[0071]
[0072]
[0073]
[0074]
[0075] Among the above compounds, compound 2, compound 33, and compound 34 were excluded due to poor water solubility, and the remaining 37 compounds were tested as candidate inhibitors; HK2 activity test was carried out in 50 μL reaction buffer, which consisted of 10 mM glucose, 1.2 mM ATP (adenosine triphosphate), 2.5 μL HK2 (0.1 mg / mL) and 25 mM Tris-HCl buffer and 5 mM MgCl2, with a pH value of 7.5. 37 candidate inhibitors of different concentrations were added, and the volume ratio of reaction buffer to candidate inhibitor was 1:1. The concentration of candidate inhibitor was selected from 1 μmol / L, 10 μmol / L, 100 μmol / L and 1 mmol / L according to experimental needs. The reaction mixture was placed on a heated shaking reactor and incubated at 37°C for 60 minutes. The reaction was stopped by adding TFA (trifluoroacetic acid terminator) to a final concentration of 2% (v / v). Each small molecule inhibitor had 3 parallel experiments. Take the solution after the reaction is terminated and add an equal volume of 0.5 mM glucose-1- 13 C after mixing, take 1 μL as the sample to be analyzed for mass spectrometry detection.
[0076] Preparation of GDs: Step A): Synthesis of Graphite Dots
[0077] The initial graphite dots were obtained by electrochemical corrosion. First, two graphite rods (99.99%, AlfaAesar Co. Ltd) were inserted into deionized water in parallel, one as the anode and the other as the cathode, and the static voltage between the two poles was ensured to be 30V. The entire electrolysis process lasted for two weeks, and high-intensity magnetic stirring was maintained to produce the initial graphite quantum dots. However, the graphite quantum dot solution at this time was still mixed with large pieces of graphite particles, so it was necessary to filter and high-speed centrifuge (22000rpm, 30min) to obtain graphite dots with uniform particle size and very good water solubility.
[0078] Step B): Preparation of reduced graphite dots
[0079] Sodium borohydride reduction is a mild process that occurs at room temperature and selectively reduces only carbonyl (C=O) and epoxy groups. The specific steps are as follows: weigh 300 mg of the obtained graphite dots and dissolve them in 300 mL of water, then add an appropriate amount of sodium borohydride (concentration is 150 mM). At room temperature, stir the reaction magnetically for 6 hours. Then use a dialysis bag for 3 days to obtain reduced graphite dots (GDs). Finally, dry the product in an oven at 60°C for 12 hours.
[0080] GDs was dispersed in water at a concentration of 1 mg / mL as the matrix solution to be used. The quick drying method was used for sample preparation: 1 μL of the matrix solution was first added to the target plate, and then 1 μL of the sample to be analyzed was added to the dry matrix surface after natural drying at room temperature in a high magnetic field of 10,000 volts. After the sample was naturally dried, mass spectrometry analysis was performed directly:
[0081] The MALDI-MS instrument used was a Bruker Ultraflex III TOF / TOF mass spectrometer, which mainly used the reflection positive and negative ion modes. The instrument parameters were a 355nm Nd:YAG laser, a laser energy of 30%, corresponding to 57μJ per pulse (laser pulse duration: 3ns), and a laser spot size of approximately 50-100μm. Each sample was tested four times, and each mass spectrum accumulated 3,000 laser spots. All samples were measured under the same instrument conditions.
[0082] After mass spectrometry analysis, screening was performed according to the following screening criteria:
[0083] The concentration of the candidate inhibitor aqueous solution is 20 μmol / L, and the inhibition rate of hexokinase 2 activity is ≥ 25%;
[0084] Inhibition rate = (1-B / A) × 100%;
[0085] A is the glucose concentration in the solution before the reaction without adding the inhibitor minus the glucose concentration in the solution after the reaction without adding the inhibitor;
[0086] B is the glucose concentration in the solution before the reaction with the inhibitor minus the glucose concentration in the solution after the reaction with the inhibitor;
[0087] Glucose concentration in reaction solution = ([glucose + Na] + Mass spectrometry signal intensity / [glucose-1- 13 C+Na] + mass spectrometry signal intensity) × known glucose-1- 13 C concentration;
[0088] Screening yielded compound 8 (having the structure of formula 1 above), compound 11 (having the structure of formula 2 above), compound 13 (having the structure of formula 3 above), compound 21 (having the structure of formula 4 above) and compound 27 (having the structure of formula 5 above).
[0089] Figure 1Schematic diagram of the GLMSD platform for high-throughput screening of candidate inhibitors of hexokinase 2 (HK2); 102 concentrations × 3 parallel test experiments × 6 parallel samples, each sample tested for 10 seconds; ultra-fast small molecule drug screening detection speed: 1836 samples analyzed in 5.1 hours; the platform is connected to small molecule drug efficacy analysis without the need to transfer to other detection platforms.
[0090] Figure 2 is the inhibition rate of HK2 by 38 candidate inhibitors at 4 different concentrations; Figure 2 It can be seen that: by comparing the commonly used hexokinase 2 colorimetric screening method, it is found that the inhibition rates of the compounds obtained by the method provided by the present application and the colorimetric method are close, indicating that the GLMSD detection results provided by the present application are accurate. In the figure, the inhibition efficiency from red to purple is from strong to weak, and the gray is that the detection kit cannot detect. In addition, 3-bromopyruvic acid (3-BP, a commonly used HK2 inhibitor) was selected as a positive control, and five new small molecules (inhibitor small molecule concentration of 20 μM) including compound 8 (corresponding to the above formula 1, the inhibition rate is 44%), compound 11 (corresponding to the above formula 2, the inhibition rate is 29%), compound 13 (corresponding to the above formula 3, the inhibition rate is 42%), compound 21 (corresponding to the above formula 4, the inhibition rate is 25%) and compound 27 (corresponding to the above formula 5, the inhibition rate is 31%) were screened, showing good inhibitory ability on HK activity.
[0091] The hexokinase colorimetric method is not as widely used as the GLMSD platform because the colorimetric method monitors the changes in UV absorption at 340nm to determine the enzyme activity, but many small molecules have strong UV absorption in this range, such as compound 3, compound 4, compound 6, compound 9, compound 11, compound 23, compound 25, compound 26, compound 28 and compound 39. The absorption peaks of these compounds change the shape and position of the absorption peak to be measured, interfering with the test results. Due to this limitation, 10 compounds failed to successfully detect inhibition during conventional colorimetric detection, while compound 11 showed good inhibition in the GLMSD platform detection. Therefore, the GLMSD platform can evaluate the inhibition efficiency of all small molecules without being affected by the UV absorption peak.
[0092] Figure 3 (a) is the structural formula of compound 8, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 8 detected by the GLMSD platform;
[0093] Figure 4(a) is the structural formula of compound 11, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 11 detected by the GLMSD platform;
[0094] Figure 5 (a) is the structural formula of compound 13, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 13 detected by the GLMSD platform;
[0095] Figure 6 (a) is the structural formula of compound 21, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 21 detected by the GLMSD platform;
[0096] Figure 7 (a) is the structural formula of compound 27, (b) is the inhibition curve of HK2 enzyme obtained by compound 8 from the colorimetric kit and GLMSD, and (c) is the raw data of HK2 activity in four concentrations of compound 27 detected by the GLMSD platform;
[0097] from Figure 3 to Figure 7 It can be seen that the corresponding inhibitory effects of the five compounds, Compound 8, Compound 11, Compound 13, Compound 21 and Compound 27 at different concentrations all have good inhibitory effects on HK2.
[0098] Figure 8-1 The pharmacokinetic data of TMZ (temozolomide); (d) is the average concentration-time curve of TMZ in plasma after intraperitoneal injection of TMZ (temozolomide) in mice; (f) is the median analysis of the TMZ pharmacokinetic curve of each mouse; (g) is the multiple-dose-pharmacokinetic curve determined by GLMSD; As can be seen from Figure 8: the GLMSD platform is able to obtain the pharmacokinetic data of small molecule compound No. 27 in a targeted manner. The competitive advantages of GLMSD in pharmacokinetic research: (1) It can track the complete blood drug concentration curve of each individual; (2) It reduces the total number of mice used in the experiment. Due to the low blood sample consumption of the GLMSD method (10 μL of blood at each time point), one mouse can be used to complete the entire pharmacokinetic curve of the drug (blood sampling at 11 time points within 24 hours, with a minimum interval of 0.25 hours). The average pharmacokinetic curve of TMZ of eight mice (n=8) ( Figure 8-1 C max (33.66μg / mL), T max (0.5h), T1 / 2 (1.72h) and AUC 0-24h The detailed value of (247.05 μg / mL·h) is similar to the data from previous literature studies, proving that the GLMSD method is capable of completing pharmacokinetic studies. Figure 8-1 Middle (f) shows the mean plasma concentration of TMZ after daily administration for 5 consecutive days (8 mice).
[0099] After verifying the superiority of the GLMSD method in pharmacokinetic testing, we further applied this method to characterize the pharmacokinetic curve of compound 27. Figure 8-2 , Figure 8-2 The pharmacokinetic data of compound 27 are shown in Table 1. All 8 mice were given a single dose (compound 27 dose was 40 mg / kg). The plasma pharmacokinetic PK values are shown in Table 1. Figure 8-2 As shown in f, including C max (14.65 μg / mL), T max (2h), T 1 / 2 (4.12h) and AUC 0-24h (64.36μg / mL·h). Based on the advantage of GLMSD in detecting the entire PK curve in one mouse, we observed that 3 of the 8 mice (#2, #3, #4) showed the characteristic reabsorption peak of this small molecule inhibitor at 8h, while it was almost absent in the other 5 mice. This significant phenomenon is related to the difference in drug uptake between individuals, suggesting that compound 27 may re-enter the blood circulation through the secondary absorption pathway. After multiple consecutive administrations ( Figure 8-2 In the model of g), pharmacokinetic data of compound 27 (40 mg / kg) were collected from each mouse every day (1, 3, 6 and 8 hours after the last dose) for 5 days. Figure 8-2 e) or continuous multiple doses ( Figure 8-2 h) form of drug administration, traditional LC-MS technology is limited to obtaining a single data point of drug pharmacokinetics by sacrificing one mouse, while GLMSD can break through this limitation by providing a complete pharmacokinetic curve based on a single mouse.
[0100] Fig. 9 MSI images of drugs and metabolites (compound 27: m / z 499, lactic acid: m / z 113) in brain tissue sections; optical micrographs of H&E-stained serial sections are used as reference. Brain glioma and lateral ventricle are represented by dotted rings; color bars encode the signal intensity of three small molecules in MSI; resolution: 10 μm. Fig. 9It shows that compound 27 has the ability to penetrate the blood-brain barrier. The superimposed image of 100-1000 small molecules (the first picture on the left) clearly shows the longitudinal section structure of the brain (U87 cell transplant tumor is located in the right frontal lobe), which is consistent with the adjacent longitudinal continuous tissue sections stained with H&E (the second picture on the left). The third picture on the left shows that compound 27 is mainly present in the contour edges of the corpus callosum and hippocampus. The fourth picture on the left shows that the content of lactic acid (m / z 113.35) around the glioma implantation site is significantly higher than that in other brain tissues. Compound 27 is enriched in the glioma site, indicating that this small molecule has good permeability and can break through the blood-brain barrier.
[0101] Fig.10 (b) shows the growth curve of U87MG subcutaneous tumors in nude mice after various treatments to eliminate primary tumors, and the error bars represent mean ± sd, (n = 6); (c) shows the survival rate of mice with subcutaneous U87MG tumors after various treatments (n = 6 in each group); (d) shows representative bioluminescent images to track cancer growth in orthotopic U87-luciferase mice after various treatments. Fig.10 It can be seen that compound 27 can inhibit the growth of solid tumors. Fig.10 In b and c), the overall survival rate (OS) of mice treated with TMZ and compound 27 was the best. The median survival time of TMZ+compound 27 (58 days) was significantly longer than that of other treatment groups: PBS (15 days), 3-BP (17 days), compound 27 (30 days), TMZ (35 days) and TMZ+3-BP (35 days). These experimental results show that as an HK2 inhibitor, compound 27 has good drug adaptability when combined with chemotherapeutic drugs such as TMZ for cancer treatment. ( Fig.10 (d) Single-agent treatment with TMZ or compound 27 alone delayed glioma growth compared with PBS. However, glioma-induced mouse mortality was reduced only during the first 20 days of treatment. After this period, the survival of both single-agent groups with orthotopic U87 heteroplastic tumors rapidly declined due to malignant gliomas. In sharp contrast, the TMZ combined with compound 27 treatment group could inhibit the bioluminescent U87 glioma and significantly improve the survival rate.
[0102] Fig.11 is the antiproliferative activity of compound 27 on brain glioma cells U87; Fig.11 It can be seen that compound 27 can inhibit the growth of U87 and kill half of the tumor cells at a concentration of 11.31 μM.
[0103] Fig.12(e) is a schematic diagram of the binding structure of the comp-27-HK complex predicted by Glide XP docking simulation; (f) is a two-dimensional schematic diagram of the binding mode of the comp-27-HK complex with hydrogen bonds and strong hydrophobic interactions. The active site residues Phe156, His159, Ser155, Cys158, Asn235, Asp209, Glu294, Ile229, Asn208 and Glu260 of HK2 all bind to compound 27. Among them, Asp209, Ile229 and Glu260 on HK2 are the most critical for the binding of compound 27. Glu260 forms a hydrogen bond with the nitrogen atom of the amide, and residue Asp209 forms two hydrogen bonds. The hydrophobic contact between Ile229 and the benzene ring of compound 27 (arene-H interaction) also contributes to the binding. Fig.12 It is proved that the small molecule compound 27 has more binding sites with HK enzyme.
[0104] Fig.13 The difference in interaction scores between compounds 27 and 3-Br at each residue (Eintcompd27-Eint3-Br) is shown, where the important residues (amino acid residues that make up the dehydrated form of the protein) are highlighted. The Glide module in the PCR product calculates the total interaction energy, van der Waals force and hydrogen bond fraction between the ligand and protein residues; through theoretical calculations, the small molecule compound 27 has a stronger binding force with the HK enzyme than the commonly used HK enzyme inhibitor 3-Br. The comparison of the binding mechanism between compound 27 and 3-BP is presented in the figure, showing that compound 27 has more binding sites with HK2, which may be the reason why compound 27 has a better inhibitory effect on HK2 activity.
[0105] Fig.14 The graph is a test chart of the antiproliferative activity of compound 8, compound 11, compound 13 and compound 21 on brain glioma cells U87. Fig.14 It can be seen that the above four small molecule compounds screened by the GLMSD platform all have inhibitory effects on U87.
[0106] Example 2 Targeted metabolomics analysis
[0107] 1. Metabolite Extraction
[0108] Collect 1×10 7Cells (number of cells per sample) were quenched with a freshly prepared quencher and centrifuged (1000×g, 1 min) to remove the cell supernatant. The cells were resuspended with 100 μL of ultrapure water and mixed. After adding 800 μL of cold methanol:acetonitrile (1:1, v / v), the mixed cell sample was sonicated in an ice bath for 30 min. The mixture was stored at -20°C for 1 h to precipitate the protein. After centrifugation at 4°C (14000×g, 20 min), the supernatant was collected, freeze-dried, and stored at -80°C before analysis by GC-MS;
[0109] 2. Sample testing
[0110] The lyophilized samples were resuspended in a solution (acetonitrile: water, 1:1, v / v, 100 μL) and then centrifuged at 4°C (14000×g, 10 min). The supernatant (100 μL) was collected and diluted with an acetonitrile solution (100 μL) and loaded with an Agilent 1290 Infinity LC system (Agilent Technologies, Beijing, China) and a 5500QTRAP mass spectrometer (ABSciex, Toronto, Canada) at 4°C for GS-MS sample loading. Chromatographic separation was performed on an ACQUITY-UPLC-BEH column (1.7 μm, 2.1 mm×150 mm; Waters Technology (Shanghai) Co., Ltd.) at a flow rate of 300 μL / min, where solvent A (mobile phase) was 15 mM ammonium acetate aqueous solution and solvent B was acetonitrile. The chromatographic conditions of gradient elution were decreased from 90% B to 40% B, and then increased sharply from 40% B to 90% B after 18 minutes. After 0.1 minutes, the volume ratio of 90% B was maintained for 4.9 minutes. The whole process lasted for 23 minutes. To monitor the stability of the system, equal volumes of complexes were extracted from 32 actual samples to process the quality control (QC) samples and put into the real samples. The mass spectrometry experiment was carried out in negative ionization and multiple reaction monitoring mode, with the following parameters: source temperature 450℃, nebulizer gas (GS1): 45, auxiliary gas (GS2): 45, curtain gas (CUR): 30, ion space voltage floating (ISVF): -4500V.
[0111] 3. Data processing
[0112] Standard GC-MS data were processed using analytical software (AB Sciex, Toronto, Canada), including conversion of raw mass spectrometric data into data containing m / z, measurement of corresponding ion intensities and retention times, and subsequent statistical analysis. Peak detection and calibration of all samples were compared with their chemical standards (Sigma-Aldrich). The data matrix was uploaded to MetaboAnalyst 5.0 for principal component analysis (PCA) and hierarchical cluster analysis (HCA).
[0113] 4. Flow cytometry experiment
[0114] In DMEM medium, 5 × 10 5 U87 cells were seeded in 24-well plates. After 24 hours of culture, compound 27 (final concentration 20 μM) was added directly to the cell growth medium, incubated at 37°C for 24 hours, briefly digested with trypsin, washed twice with cold PBS, centrifuged (2000 rpm, 5 minutes), the supernatant medium was discarded, and the cells were washed twice with cold PBS. The cells (1×10 5 Cells / mL). 5 μL Annexin V-FITC was added to the cell suspension and incubated at 4°C for 15 minutes. The cells were then gently mixed with another dye PI (10 μL). The cells were collected and analyzed by flow cytometry. Data analysis was performed using CFLow Plus (AccuriCytometers).
[0115] Fig.15 Normalization of reprogrammed metabolic pathways in glioma U87 cells after Compound 27 treatment. Among them, a, relative difference heat map of aggregated metabolites of U87 cells treated with Compound 27 and blank control, n=5; b, quantitative analysis of metabolomics changes of U87 cells in glycolysis and TCA cycle. Statistical significance was analyzed by t-test. *: P<0.05; ***: P<0.01; ***: P<0.005. c, visualization of differential glycolytic metabolite expression after Compound 27 inhibition. The applicant observed changes in reprogrammed metabolic pathways in U87 glioma cells treated with the HK2 candidate inhibitor (Compound 27), with significantly different metabolite cluster expressions compared with the PBS-treated control group ( Fig.15(a). Assessing hexokinase (HK2 in cancer cells), the first and rate-limiting enzyme in the glycolytic pathway, metabolomic analysis showed that the concentration of glucose-6-phosphate, a direct product of hexokinase, was lower than that of the control group. The reduction of glycerol-3-phosphate, phosphoenolpyruvate, and pyruvate indicated that compound 27 inhibited glycolysis in U87 cells, thereby reducing the basic energy reserve for tumor growth. Due to the inhibition of HK2 by compound 27, the abnormal pentose phosphate pathway (PPP) of U87 was also inhibited. Both the precursor (α-D-ribose-5-phosphate) and the key cofactor (nicotinamide adenine dinucleotide phosphate, NADPH) for ribose backbone nucleotide synthesis were reduced, thereby limiting the ribose supply through PPP DNA synthesis required for tumor proliferation. In addition, previous reports have shown that glycerate-3-phosphate is also an important metabolic intermediate in the serine synthesis pathway (SSP). After treatment with Compound 27, the glyceraldehyde-3-phosphate in U87 cells decreased significantly by nearly two orders of magnitude (P<0.005), indicating that U87 cells were deficient in the de novo synthesis of serine and glycine. The blockade of citrate production in the TCA cycle (p<0.0001) further inhibited the synthesis of FA in U87 cells, resulting in insufficient lipids that could not meet the needs of tumor cell activity. In addition, the applicant found that after treatment with Compound 27, the concentration of thiamine pyrophosphate (TPP) increased by nearly 2.5 times, and thiamine pyrophosphate is a key coenzyme that converts pyruvate into acetyl-CoA by regulating the activity of pyruvate dehydrogenase (PDH), and promotes the apoptosis of U87 cells by reducing the glucose metabolic flux of TCA. Glyceraldehyde-3-phosphate and α-D-ribose-5-phosphate are intermediate metabolites in the glycolysis pathway and can undergo reversible changes. The experiments showed that compound 27 normalized the pentose phosphate pathway, reduced the production of α-D-ribose-5-phosphate, and accumulated glyceraldehyde-3-phosphate (approximately 3.5 times higher than the PBS-treated control group). Together, these data revealed important changes in the normalization of metabolic pathways in U87 cells induced by compound 27.
[0116] To further confirm the occurrence of cell apoptosis, the applicant used annexin V / propidium iodide double staining to detect exposed phosphatidylserine and observe cell membrane damage. Fig.16 , Fig.16For flow cytometric analysis of compd27-induced apoptosis of U87 cells (Annexin V-FITC / PI staining), two major cell populations were observed by flow cytometry: compared with the control group, the early (Annexin+ / PI-) and late (Annexin+ / PI+) apoptotic cells in the compound 27 treatment group accounted for 31.2% and 30.6%, respectively, while in the blank control group, the proportion of U87 damaged cells was only 2.06% and 2.04%. These results indicate that the glycolysis inhibition pathway of compound 27 is involved in the apoptosis of glioma cells.
[0117] As can be seen from the above examples, the present invention provides a method for screening hexokinase 2 inhibitors, comprising the following steps: mixing a candidate inhibitor with a buffer, incubating, terminating the reaction, and obtaining a post-reaction solution; the buffer comprising hexokinase 2 and glucose; mixing the post-reaction solution with an equal volume of glucose-1- 13 C and mixed to obtain the analyte; the analyte is added dropwise to the surface of the graphite structure nanomaterial matrix, and after drying, MALDI-MS detection is performed to screen and obtain hexokinase 2 inhibitors. This method uses graphite structure nanomaterials as a matrix, combined with MALDI-MS detection, ultra-fast screening and detection (analyzing 1836 samples within 5.1 hours); a series of small molecule drugs with high inhibitory activity on brain tumor growth are obtained; small molecule drug efficacy analysis is docked without the need to transfer to other detection platforms.
[0118] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of small molecule compounds in the preparation of anti-tumor drugs; the tumor is brain glioma; The small molecule compound has a structure of Formula 5, Formula 42, Formula 44 or Formula 45: Formula 5, Formula 42, Formula 44, Formula 45.
2. The use according to claim 1, characterized in that: The small molecule compound has an inhibitory effect on key proteases in abnormal glycolysis caused by metabolic reprogramming in tumor cells, and is used alone as a drug molecule or in combination with other known drugs to kill tumor cells.
3. The use according to claim 1, characterized in that: The small molecule compound can inhibit the abnormal metabolic pathways of tumor cells and hinder their ability to repair damaged DNA during chemotherapy; The small molecule compound can break through the limitation of the blood-brain barrier and be taken up and enriched in the tumor site which is difficult for conventional drugs to reach.
4. The use according to claim 1, characterized in that: In the case of a single or multiple injections of the small molecule compound, a mass spectrometry quantitative analysis of the drug molecules is performed on a blood sample of less than 10 microliters, so that pharmacokinetic data can be collected in a single model animal.
